Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies.
Disease Burden
Hyperphagia
Leptin Receptor
Melanocortin Receptor
Pro-Opiomelanocortin
Rare Genetic Diseases of Obesity
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
20
12
2021
accepted:
26
01
2022
pubmed:
23
2
2022
medline:
12
4
2022
entrez:
22
2
2022
Statut:
ppublish
Résumé
In patients with pro-opiomelanocortin (POMC) or leptin receptor (LEPR) deficiency, managing obesity and hyperphagia can be burdensome for patients and caretakers. The impacts on health-related quality of life are under-recognized and are not well characterized. We conducted in-depth qualitative interviews in patients with POMC (n = 3) and LEPR (n = 2) deficiencies participating in an ongoing open-label extension of phase 3 clinical trials with the melanocortin receptor 4 agonist setmelanotide to describe the patient experience of hyperphagia and characterize changes following treatment with setmelanotide. Prior to setmelanotide treatment, all five patients described abnormal sensations of hunger with none indicating feeling satiated after meals and also reported that the burden of hyperphagia impacted their families, emotions, and work and/or school functioning. Following setmelanotide treatment, all five patients reported consistent reductions in hunger and weight, decreased eating, and feeling satiated after meals in addition to substantial improvements in each area of functioning they had previously reported. All five patients indicated they were very satisfied with the impact of setmelanotide on their quality of life and would be upset if treatment was discontinued. In patients with POMC or LEPR deficiency, hyperphagia and the inability to feel satiety negatively impacted quality of life. By reducing hunger and improving satiety, setmelanotide facilitated important changes in the lives of these patients. This qualitative research study suggests that the impact of setmelanotide goes beyond favorable clinical changes (e.g., weight and hunger) to also include quality of life improvements that are highly meaningful to patients.
Identifiants
pubmed: 35192151
doi: 10.1007/s12325-022-02059-8
pii: 10.1007/s12325-022-02059-8
pmc: PMC8862005
doi:
Substances chimiques
setmelanotide
0
alpha-MSH
581-05-5
Pro-Opiomelanocortin
66796-54-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1772-1783Informations de copyright
© 2022. The Author(s).
Références
Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16:36–46.
doi: 10.1016/S1470-2045(14)71123-4
Jia H, Lubetkin EI. The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Oxf). 2005;27:156–64.
doi: 10.1093/pubmed/fdi025
Centers for Disease Control and Prevention. Childhood obesity causes and consequences. 2021. https://www.cdc.gov/obesity/childhood/causes.html#:~:text=Obesity%20during%20childhood%20can%20harm,are%20more%20likely%20to%20have%3A&text=High%20blood%20pressure%20and%20high,resistance%2C%20and%20type%202%20diabetes . Updated March 19, 2021. Accessed 06 Apr 2021.
Ramos Salas X, Forhan M, Caulfield T, et al. Addressing internalized weight bias and changing damaged social identities for people living with obesity. Front Psychol. 2019;10:1409.
doi: 10.3389/fpsyg.2019.01409
Ford ES, Moriarty DG, Zack MM, et al. Self-reported body mass index and health-related quality of life: findings from the behavioral risk factor surveillance system. Obes Res. 2001;9:21–31.
doi: 10.1038/oby.2001.4
Schwimmer JB, Burwinkle TM, Varni JW. Health-related quality of life of severely obese children and adolescents. JAMA. 2003;289:1813–9.
doi: 10.1001/jama.289.14.1813
Katz DA, McHorney CA, Atkinson RL. Impact of obesity on health-related quality of life in patients with chronic illness. J Gen Intern Med. 2000;15:789–96.
doi: 10.1046/j.1525-1497.2000.90906.x
Nigatu YT, Bültmann U, Reijneveld SA. The prospective association between obesity and major depression in the general population: does single or recurrent episode matter? BMC Public Health. 2015;15:350.
doi: 10.1186/s12889-015-1682-9
Nigatu YT, Reijneveld SA, de Jonge P, et al. The combined effects of obesity, abdominal obesity and major depression/anxiety on health-related quality of life: the LifeLines Cohort Study. PLoS ONE. 2016;11: e0148871.
doi: 10.1371/journal.pone.0148871
Albuquerque D, Nobrega C, Manco L, Padez C. The contribution of genetics and environment to obesity. Br Med Bull. 2017;123:159–73.
doi: 10.1093/bmb/ldx022
da Fonseca ACP, Mastronardi C, Johar A, et al. Genetics of non-syndromic childhood obesity and the use of high-throughput DNA sequencing technologies. J Diabetes Complicat. 2017;31:1549–61.
doi: 10.1016/j.jdiacomp.2017.04.026
Huvenne H, Dubern B, Clement K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9:158–73.
doi: 10.1159/000445061
Heymsfield SB, Avena NM, Baier L, et al. Hyperphagia: current concepts and future directions proceedings of the 2nd International Conference on Hyperphagia. Obesity (Silver Spring). 2014;22(suppl 1):S1–17.
doi: 10.1002/oby.20646
Clement K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8:960–70.
doi: 10.1016/S2213-8587(20)30364-8
IMCIVREE™ [package insert]. Boston, MA: Rhythm Pharmaceuticals, Inc.; 2020.
Knox J RC, Fay M, McCagg A, et al. Burden of illness associated with rare genetic disorders of obesity. In: Paper presented at: 26th European Congress on Obesity 2019; April 28–May 1, Glasgow, Scotland, 2019.